Updated treatment guideline for hormone therapy in postmenopausal women

Dae Hui Kwon, Jung-Ho Shin

Research output: Contribution to journalArticle

Abstract

Since menopause hormone therapy was first introduced, it has been widely used worldwide as the most effective treatment for vasomotor symptoms in menopausal women and for genitourinary syndrome of menopause. Menopause hormone therapy has been shown to prevent bone loss and fracture, but it may additionally offer various benefits for numerous other symptoms. The benefit-to-risk ratio of menopause hormone therapy is most favorable for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications. Longer durations of therapy should be limited to patients with documented indications, such as persistent vasomotor symptoms or bone loss. For genitourinary syndrome of menopause, low-dose vaginal estrogen therapy or other therapies are recommended. Tibolone is a synthetic steroid that provides a therapeutic effect in the treatment of menopausal symptoms.

Original languageEnglish
Pages (from-to)145-149
Number of pages5
JournalJournal of the Korean Medical Association
Volume62
Issue number3
DOIs
Publication statusPublished - 2019 Mar 1

Fingerprint

Menopause
Hormones
Guidelines
tibolone
Therapeutics
Bone Fractures
Therapeutic Uses
Estrogens
Odds Ratio
Steroids
Bone and Bones

Keywords

  • Estrogens
  • Menopause
  • Osteoporosis
  • Urogenital system
  • Vasomotor system

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Updated treatment guideline for hormone therapy in postmenopausal women. / Kwon, Dae Hui; Shin, Jung-Ho.

In: Journal of the Korean Medical Association, Vol. 62, No. 3, 01.03.2019, p. 145-149.

Research output: Contribution to journalArticle

@article{6f950457e22041ce98ae1601bb1e5335,
title = "Updated treatment guideline for hormone therapy in postmenopausal women",
abstract = "Since menopause hormone therapy was first introduced, it has been widely used worldwide as the most effective treatment for vasomotor symptoms in menopausal women and for genitourinary syndrome of menopause. Menopause hormone therapy has been shown to prevent bone loss and fracture, but it may additionally offer various benefits for numerous other symptoms. The benefit-to-risk ratio of menopause hormone therapy is most favorable for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications. Longer durations of therapy should be limited to patients with documented indications, such as persistent vasomotor symptoms or bone loss. For genitourinary syndrome of menopause, low-dose vaginal estrogen therapy or other therapies are recommended. Tibolone is a synthetic steroid that provides a therapeutic effect in the treatment of menopausal symptoms.",
keywords = "Estrogens, Menopause, Osteoporosis, Urogenital system, Vasomotor system",
author = "Kwon, {Dae Hui} and Jung-Ho Shin",
year = "2019",
month = "3",
day = "1",
doi = "10.5124/jkma.2019.62.3.145",
language = "English",
volume = "62",
pages = "145--149",
journal = "Journal of the Korean Medical Association",
issn = "1975-8456",
publisher = "Korean Medical Association",
number = "3",

}

TY - JOUR

T1 - Updated treatment guideline for hormone therapy in postmenopausal women

AU - Kwon, Dae Hui

AU - Shin, Jung-Ho

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Since menopause hormone therapy was first introduced, it has been widely used worldwide as the most effective treatment for vasomotor symptoms in menopausal women and for genitourinary syndrome of menopause. Menopause hormone therapy has been shown to prevent bone loss and fracture, but it may additionally offer various benefits for numerous other symptoms. The benefit-to-risk ratio of menopause hormone therapy is most favorable for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications. Longer durations of therapy should be limited to patients with documented indications, such as persistent vasomotor symptoms or bone loss. For genitourinary syndrome of menopause, low-dose vaginal estrogen therapy or other therapies are recommended. Tibolone is a synthetic steroid that provides a therapeutic effect in the treatment of menopausal symptoms.

AB - Since menopause hormone therapy was first introduced, it has been widely used worldwide as the most effective treatment for vasomotor symptoms in menopausal women and for genitourinary syndrome of menopause. Menopause hormone therapy has been shown to prevent bone loss and fracture, but it may additionally offer various benefits for numerous other symptoms. The benefit-to-risk ratio of menopause hormone therapy is most favorable for women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications. Longer durations of therapy should be limited to patients with documented indications, such as persistent vasomotor symptoms or bone loss. For genitourinary syndrome of menopause, low-dose vaginal estrogen therapy or other therapies are recommended. Tibolone is a synthetic steroid that provides a therapeutic effect in the treatment of menopausal symptoms.

KW - Estrogens

KW - Menopause

KW - Osteoporosis

KW - Urogenital system

KW - Vasomotor system

UR - http://www.scopus.com/inward/record.url?scp=85065479646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065479646&partnerID=8YFLogxK

U2 - 10.5124/jkma.2019.62.3.145

DO - 10.5124/jkma.2019.62.3.145

M3 - Article

VL - 62

SP - 145

EP - 149

JO - Journal of the Korean Medical Association

JF - Journal of the Korean Medical Association

SN - 1975-8456

IS - 3

ER -